Showing results (2451-2460 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 3, 2011
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cellsPablo E Morande, Samanta R Zanetti, Mercedes Borge, et al.
Investigational New Drugs|November 10, 2011
Nilotinib in patients with metastatic melanoma harboring KIT gene aberrationJin Hyun Cho, Kyoung Mee Kim, Miyeon Kwon, et al.
Investigational New Drugs|March 15, 2012
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumoursYasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata, et al.
Investigational New Drugs|March 15, 2012
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemiasPatrick Ziegler, Tuhama Chahoud, Thomas Wilhelm, et al.
Investigational New Drugs|March 15, 2012
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancerA Dasari, L Gore, W A Messersmith, et al.
Investigational New Drugs|March 20, 2012
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinomaThomas Yau, P N Cheng, Pierre Chan, et al.
Investigational New Drugs|February 29, 2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M Annunziata, Elise C Kohn, Patricia LoRusso, et al.
Investigational New Drugs|April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trialsAntonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Investigational New Drugs|February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelMichael Millward, Paul Mainwaring, Alain Mita, et al.
Investigational New Drugs|March 16, 2011
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancerElwyn C Cabebe, George A Fisher, Branimir I Sikic
Pageof 372